The court will decide whether Myriad Genetics, a biotechnology company, has the right to patent human genes — in this case, two gene mutations called BRCA1 and BRCA2 that increase breast cancer ...

After the patents run out, revenues plummet as generic copies hit the market. The breakthrough drugs of the young biotech industry are now starting to run out of patent life, and Congress is ...

The court has applied the doctrine to biotechnology patents—specifically those claiming genuses of antibodies, DNA sequences or other biologic molecules (i.e., molecules made by processes ...